{"analyses":[{"ciLowerLimit":"71.45","ciPctValue":"95","ciUpperLimit":"77.57","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","pValueComment":"The Holm step down method of multiple comparisons was used to maintain a study wide type I error of 5% for prespecified secondary efficacy analyses. The 2-sided type I error rate was 0.025 for this analysis.","paramType":"Difference in response rates","paramValue":"74.51","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.1","upperLimit":"80.7","value":"78"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"5.0","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"854"},{"groupId":"OG001","value":"777"}],"units":"Participants"}],"description":"PSA response was defined as a ≥ 50% reduction in PSA from baseline to the lowest postbaseline PSA value and required confirmation by a consecutive assessment at least 3 weeks later. Patients were evaluable for PSA response rate if a patient had a PSA level measured at baseline and at least one postbaseline assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth.","id":"OG000","title":"Enzalutamide"},{"description":"Participants received placebo, administered as four capsules, once per day by mouth.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Evaluable intent to treat (ITT) population - All patients randomly assigned to treatment with PSA values at baseline and at least one postbaseline assessment.","reportingStatus":"POSTED","timeFrame":"During study period (up to 3 years)","title":"Percentage of Patients With Prostate Specific Antigen (PSA) Response ≥ 50%","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}